---
document_datetime: 2023-09-21 20:22:23
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/braftovi-all-authorised-presentations_en.pdf
document_name: braftovi-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8470065
conversion_datetime: 2025-12-20 17:06:52.737574
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

| EU/1/18/1314/001   | Braftovi   | 50 mg   | Capsule, hard   | Oral use   | blister (PA/alu/PVC/alu/ PET/paper)   | 28x1 capsules (unit dose)   |
|--------------------|------------|---------|-----------------|------------|---------------------------------------|-----------------------------|
| EU/1/18/1314/002   | Braftovi   | 75 mg   | Capsule, hard   | Oral use   | blister (PA/alu/PVC/alu/ PET/paper)   | 42x1 capsules (unit dose)   |
| EU/1/18/1314/003   | Braftovi   | 50 mg   | Capsule, hard   | Oral use   | blister (PA/alu/PVC/alu/ PET/paper)   | 112x1 capsules (unit dose)  |
| EU/1/18/1314/004   | Braftovi   | 75 mg   | Capsule, hard   | Oral use   | blister (PA/alu/PVC/alu/ PET/paper)   | 168x1 capsules (unit dose)  |